AIMS AND BACKGROUND: Exfoliated cells in human stool offer excellent opportunities to non-invasively detect molecular markers associated with colorectal tumorigenesis, and to evaluate the effects of exposures to exogenous and endogenous carcinogenic or chemopreventive substances. This pilot study investigated the feasibility of determining DNA methylation and RNA expression simultaneously in stool specimens treated with a single type of nucleic acid preservatives. METHODS: Stool specimens from 56 volunteers that were preserved up to a week with RNA later were used in this study. Bisulfite sequencing was used to determine methylation at 27 CpG loci on the estrogen receptor 1 (ESR1) promoter. Taqman assay was used for quantitative reverse transcription polymerase chain reactions to measure cyclooxygenase 2 (COX2) and epidermal growth factor receptor (EGFR) mRNA expression. Subjects' basic demographic and other selected risk factors for colorectal cancer were captured through questionnaires and correlated with the levels of these markers. RESULTS: Less than 10% of the samples failed in individual assays. Overall, 24.0% of the CpG loci on the ESR1 promoter were methylated. COX2 expression and alcohol use were positively correlated; an inverse association was present between EGFR expression and cigarette smoking; and subjects using anti-diabetic medication had higher ESR1 methylation. In addition, higher EGFR expression levels were marginally associated with history of polyps and family history of colorectal cancer. CONCLUSIONS: The present study demonstrates that simultaneous analyses for DNA and RNA markers are feasible in stool samples treated with a single type of nucleotide preservatives. Among several associations observed, the association between EGFR expression and polyps deserves further investigation as a potential target for colorectal cancer screening. Larger studies are warranted to confirm some of our observations.
AIMS AND BACKGROUND: Exfoliated cells in human stool offer excellent opportunities to non-invasively detect molecular markers associated with colorectal tumorigenesis, and to evaluate the effects of exposures to exogenous and endogenous carcinogenic or chemopreventive substances. This pilot study investigated the feasibility of determining DNA methylation and RNA expression simultaneously in stool specimens treated with a single type of nucleic acid preservatives. METHODS: Stool specimens from 56 volunteers that were preserved up to a week with RNA later were used in this study. Bisulfite sequencing was used to determine methylation at 27 CpG loci on the estrogen receptor 1 (ESR1) promoter. Taqman assay was used for quantitative reverse transcription polymerase chain reactions to measure cyclooxygenase 2 (COX2) and epidermal growth factor receptor (EGFR) mRNA expression. Subjects' basic demographic and other selected risk factors for colorectal cancer were captured through questionnaires and correlated with the levels of these markers. RESULTS: Less than 10% of the samples failed in individual assays. Overall, 24.0% of the CpG loci on the ESR1 promoter were methylated. COX2 expression and alcohol use were positively correlated; an inverse association was present between EGFR expression and cigarette smoking; and subjects using anti-diabetic medication had higher ESR1 methylation. In addition, higher EGFR expression levels were marginally associated with history of polyps and family history of colorectal cancer. CONCLUSIONS: The present study demonstrates that simultaneous analyses for DNA and RNA markers are feasible in stool samples treated with a single type of nucleotide preservatives. Among several associations observed, the association between EGFR expression and polyps deserves further investigation as a potential target for colorectal cancer screening. Larger studies are warranted to confirm some of our observations.
Authors: Renata A Coudry; Sibele I Meireles; Radka Stoyanova; Harry S Cooper; Alan Carpino; Xianqun Wang; Paul F Engstrom; Margie L Clapper Journal: J Mol Diagn Date: 2007-02 Impact factor: 5.568
Authors: Gary M Clark; Denni M Zborowski; Pedro Santabarbara; Keyue Ding; Marlo Whitehead; Lesley Seymour; Frances A Shepherd Journal: Clin Lung Cancer Date: 2006-05 Impact factor: 4.785
Authors: Wai K Leung; Ka-Fai To; Ellen P S Man; Michael W Y Chan; Aric J Hui; Simon S M Ng; James Y W Lau; Joseph J Y Sung Journal: Am J Gastroenterol Date: 2007-03-22 Impact factor: 10.864
Authors: Michael A Pereira; Lianhui Tao; Wei Wang; Yingzhe Li; Asad Umar; Vernon E Steele; Ronald A Lubet Journal: Carcinogenesis Date: 2004-06-17 Impact factor: 4.944
Authors: Manon van Engeland; Matty P Weijenberg; Guido M J M Roemen; Mirian Brink; Adriaan P de Bruïne; R Alexandra Goldbohm; Piet A van den Brandt; Stephen B Baylin; Anton F P M de Goeij; James G Herman Journal: Cancer Res Date: 2003-06-15 Impact factor: 12.701
Authors: Steven Itzkowitz; Randall Brand; Lina Jandorf; Kris Durkee; John Millholland; Linda Rabeneck; Paul C Schroy; Stephen Sontag; David Johnson; Sanford Markowitz; Lawrence Paszat; Barry M Berger Journal: Am J Gastroenterol Date: 2008-08-27 Impact factor: 10.864
Authors: K Sugio; H Uramoto; K Ono; T Oyama; T Hanagiri; M Sugaya; Y Ichiki; T So; S Nakata; M Morita; K Yasumoto Journal: Br J Cancer Date: 2006-03-27 Impact factor: 7.640
Authors: John B Kisiel; Megan M Garrity-Park; William R Taylor; Thomas C Smyrk; David A Ahlquist Journal: Inflamm Bowel Dis Date: 2013-09 Impact factor: 5.325